SCHEDULE: Activist DOMA Demands Pacira CEO Ouster, Company Sale

Activist investor DOMA Perpetual Capital Management, holding 7.3% of Pacira BioSciences, has nominated three directors and called for the immediate replacement of CEO Frank Lee and a formal sale process for the company.

Summary

• DOMA Perpetual Capital Management LLC and its affiliates (collectively, "DOMA") beneficially own approximately 7.3% of Pacira BioSciences, Inc.'s outstanding common shares.
• DOMA has nominated three director candidates—Christopher Dennis, Oliver Benton Curtis III, and Eric de Armas—for election to Pacira's Board of Directors at the 2026 annual meeting of stockholders.
• DOMA intends to solicit proxies in support of its nominees.
• DOMA has publicly called for the immediate replacement of Pacira's CEO, Frank Lee, and the appointment of an interim CEO.
• DOMA urges the Board to initiate a formal sale process for Pacira to maximize shareholder value.
• DOMA believes the current Board lacks financial controls, sophistication, and legal expertise, and has failed in management oversight.
• DOMA criticizes Pacira's stock performance, noting declines of 56% over the last decade, 68% over the last five years, and 30% under CEO Frank Lee.
• DOMA highlights Pacira's consistent missed earnings, continuous lowering of guidance, and a complete lack of combined profitability in the last two years.
• DOMA asserts that management compensation is unsustainable, approaching 7% of the firm's entire market capitalization, and that CEO Frank Lee's compensation in the last two years exceeded total earnings per share distributed to all shareholders.
• DOMA believes EXPAREL is a valuable asset whose potential has been undermined by current management's strategic and operational execution.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as having a moderately positive sentiment for shareholders, as it signals strong activist pressure to unlock value through potential management changes and a company sale, despite the underlying negative performance highlighted by DOMA.

Positives

• DOMA believes EXPAREL is a valuable asset with significant potential, especially as the only non-opioid pain medication for surgical settings in the U.S.
• The proposed sale of Pacira to a larger firm could accelerate EXPAREL's distribution and application, potentially benefiting patients and providers.
• The nomination of directors with experience in strategic capital allocation, risk management, healthcare, internal investigations, litigation, and due diligence could improve Board oversight and strategic direction.

Negatives

• Pacira's stock price has declined 56% over the last decade and 68% over the last five years.
• Under CEO Frank Lee's leadership, the stock has fallen 30%.
• The company has consistently missed earnings and continuously lowered guidance, which was then missed.
• Pacira has shown a complete lack of combined profitability in the last two years.
• Management executive compensation is approaching 7% of the firm's entire market capitalization, deemed unsustainable by DOMA.
• CEO Frank Lee's compensation in the last two years exceeded the total earnings per share distributed to all shareholders combined.
• The Board approved wasteful expenditures, including relocating the company's headquarters to San Francisco without clear strategic justification and at significant cost to shareholders.
• DOMA expresses concern that the Board's actions may potentially constitute gross negligence.

Risks

• The Board's actions may potentially constitute gross negligence, according to DOMA.
• Taking further risk with IP battles could negatively impact the company.
• Sustained underperformance due to management's strategic and operational execution continues to be a challenge.

Future Outlook

DOMA intends to solicit proxies to elect its three director nominees to the Board, aiming to improve financial controls, sophistication, and legal expertise, and develop increased management oversight. DOMA also seeks the immediate replacement of the current CEO and a formal sale process for Pacira to maximize shareholder value and accelerate the distribution of EXPAREL.

Management Comments

• "Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Years; Under the Leadership of CEO and Board Member Frank Lee, the Stock Has Fallen 30%; The Company's Underperformance is Reflected in Consistently Missed Earnings, Continuous Lowering of Guidance, Which is Then Missed, and a Complete Lack of Combined Profitability in the Last Two Years."
• "We believe the Stock Price Reflects the Market's Lack of Trust in Management and the Board of Directors' Utter Failure of Oversight."
• "DOMA Asserts Frank Lee Should be Replaced Immediately; the Board Should Name an Interim CEO and Conduct a Formal Sale Process of the Business."
• "DOMA believes electing these nominees is critical to address the Board's lack of financial controls, sophistication and legal expertise, and to develop proper management oversight at the Board level."
• "The Board has spent years generating zero value for shareholders while lavishly compensating its executives and members."
• "Management executive compensation is unsustainable, currently approaching 7% of the Firm's entire market capitalization."
• "The Board should immediately engage bankers to proceed with a sale of the Company, discontinuing future acquisitions of pipeline drugs and maximizing returns and returning capital to its rightful owners, the Company's shareholders."
• "By selling Pacira to a larger firm, the Company can ensure that shareholders finally receive the return they deserve and a larger, savvier company will be able to accelerate the distribution and application of this incredible drug."

Industry Context

StockSavvy.ai notes that this filing represents a significant activist investor challenge in the biotechnology sector. DOMA's aggressive stance, including calls for CEO replacement and a company sale, is characteristic of activist campaigns targeting companies with perceived underperformance, high executive compensation, and valuable underlying assets like EXPAREL. Such actions often signal a belief that a company's strategic direction and governance are failing to unlock shareholder value, prompting external intervention to force change or a liquidity event.

Comparison to Industry Standards

• Pacira's stock performance, with declines of 56% over a decade and 68% over five years, significantly underperforms typical growth expectations for a biotech company, especially one with a key asset like EXPAREL, suggesting a substantial deviation from industry benchmarks.
• The reported 'complete lack of combined profitability in the last two years' contrasts sharply with the financial health expected of established pharmaceutical or biotech firms, indicating a failure to meet fundamental operational efficiency standards.
• Management executive compensation approaching 7% of the firm's market capitalization is an unusually high ratio, particularly when coupled with poor financial performance and stock decline, suggesting a disconnect from industry best practices for performance-based compensation.
• The claim that CEO Frank Lee's compensation exceeded total earnings per share distributed to all shareholders combined in the last two years points to a compensation structure that is out of alignment with shareholder returns, a metric often scrutinized against industry peers.

Management Changes

Corporate Governance

Legal Proceedings

• DOMA has privately notified Board members of its concern that the Board's actions may potentially constitute gross negligence.

Stakeholder Impact

• Shareholders: Potential for increased value through a company sale or improved governance and strategic execution. Current shareholders have experienced significant stock price declines and poor returns.
• Management: Current CEO Frank Lee faces a call for immediate replacement. Other executives may face increased scrutiny or changes in compensation structure.
• Employees: Potential for changes in leadership and strategic direction could impact employee morale, roles, and future employment if a sale or restructuring occurs.
• Customers/Patients: A sale to a larger firm could potentially accelerate the distribution and application of EXPAREL, benefiting patients by offering an effective alternative to opioid pain management.
• Creditors: A company sale or significant strategic shift could alter the company's financial profile and risk, potentially impacting creditors.

Next Steps

• DOMA Perpetual Capital Management LLC intends to file a preliminary proxy statement and accompanying WHITE universal proxy card with the SEC.
• DOMA will solicit votes for the election of its slate of director nominees at Pacira's 2026 annual meeting of stockholders.
• DOMA urges the Board to immediately engage bankers to proceed with a formal sale process of the company.
• DOMA calls for the Board to discontinue future acquisitions of pipeline drugs.

Key Dates

Recommendation

A seasoned investor or institution would likely view this activist filing as a potential catalyst for unlocking shareholder value. The strong demands for CEO replacement and a formal sale process, coupled with a significant ownership stake by DOMA, suggest that substantial changes are imminent. While the underlying performance issues are negative, the activist intervention often signals an opportunity for a 'buy' recommendation, anticipating that the pressure will lead to strategic actions (like a sale) that could drive the stock price higher.

Keywords

Pacira BioSciences, PCRX, DOMA Perpetual Capital Management, Activist Investor, Proxy Fight, Director Nomination, CEO Replacement, Company Sale, EXPAREL, Corporate Governance, Shareholder Value, Biotechnology, Pharmaceuticals